Menu
Search
|

Menu

Close
X

ProQR Therapeutics NV PRQR.OQ (NASDAQ Stock Exchange Global Market)

6.70 USD
-0.05 (-0.74%)
As of Jun 15
chart
Previous Close 6.75
Open 6.40
Volume 29,377
3m Avg Volume 13,633
Today’s High 6.80
Today’s Low 6.40
52 Week High 7.20
52 Week Low 2.78
Shares Outstanding (mil) 24.11
Market Capitalization (mil) 112.31
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 3 analysts

KEY STATS

Revenue (mm, EUR)
FY18
0
FY17
1
FY16
2
FY15
3
EPS (EUR)
FY18
-0.334
FY17
-1.729
FY16
-1.675
FY15
-0.892
*Note: Units in Millions of Euro
**Note: Units in Euro

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.75
Price to Sales (TTM)
vs sector
79.24
5.71
Price to Book (MRQ)
vs sector
2.60
5.37
Price to Cash Flow (TTM)
vs sector
--
23.33
Total Debt to Equity (MRQ)
vs sector
16.54
16.44
LT Debt to Equity (MRQ)
vs sector
16.54
12.17
Return on Investment (TTM)
vs sector
-68.51
14.38
Return on Equity (TTM)
vs sector
-75.74
16.07

EXECUTIVE LEADERSHIP

Daniel De Boer
Founding Chief Executive Officer, Since 2012
Salary: --
Bonus: --
Gerard Platenburg
Co-Founder, Chief Innovation Officer, Since
Salary: --
Bonus: --
Smital Shah
Chief Financial Officer, Since 2014
Salary: --
Bonus: --
Rene Beukema
Chief Corporate Development Officer and General Counsel, Since
Salary: --
Bonus: --
David Rodman
Chief Development Strategy Officer, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Zernikedreef 9
LEIDEN     2333 CK

Phone: +31854.894932

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide, for the treatment of Leber’s congenital amaurosis (LCA), and QR-313 for the treatment of dystrophic epidermolysis bullosa (DEB).

SPONSORED STORIES